Does autoimmune thyroiditis affect the clinical course of type 1 diabetes mellitus in children, regardless of the functional state of the thyroid gland?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The combination of type 1 diabetes mellitus (DM1) and autoimmune thyroiditis (AIT) is quite common and varies in frequency from 20 to 35% among DM1 children. The literature data indicate a negative effect of the combination of these diseases on the control of DM1, frequent hypoglycemia, and a deterioration of the lipid profile in children with hypothyroidism in the AIT outcome. Objective. Evaluation of the effect of AIT on the compensation of carbohydrate metabolism and the development of microvascular complications in DM1 children regardless of the functional state of the thyroid gland. Methods. A cross-sectional study with analysis of medical records of children undergoing inpatient treatment at the Regional Endocrinology Center of the Regional Children’s Clinical Hospital with a diagnosis of autoimmune polyglandular syndrome type 3 (APS 3: DM1 + AIT) were conducted. Data on the date of manifestation and the duration of the disease, the revealed complications, the glycated hemoglobin (HbA1c), TSH, cT4, anti-thyroid peroxidase antibody (anti-TPO) levels and the results of ultrasound, as well as the presence of chronic complications (diabetic retino-, nephro-, polylineuro- and chiropathy) were recorded. The distribution into subgroups was carried out according to the TSH level: euthyroidism (ET): 0.4-5.0 цЮ/L; subcompensated hypothyroidism (SCHT): 5.0-10.0 цЮ/L; drug-compensated hypothyroidism (DCHT): 0.4-5.0 цЮ/L on sodium levothyroxine; and analysis of AIT catamnesis. Results. The main group included 112 children diagnosed with APS 3. According to the functional state of the thyroid gland, ET was observed in 38.4% of cases (n=43), SCHT - in 42% (n=47), DCHT - in 19.6% (n=22). In general, in children with APS 3, regardless of the thyroid function in the outcome of AIT, the HbA1c level was significantly higher compared to the control group (n=77; 9.8 versus 8.7%; p=0.001), including with ET - 9.7%, with SCHT - 9.5%, and with the greatest differences with DCHT - 10.3%. The frequency of diabetes complications in the groups did not differ, but in the main group, diabetic nephropathy was significantly more often diagnosed, as well as the presence of several complications at once. The highest complication rate was found in the DCHT group - 68.2% (n=15), in the subgroups of children with ET and SCHT - 39.5% (n=17) and 46.8% (n=22), respectively. Children with DCHT had a higher incidence of nephropathy. Hyropathy was rare in both groups, however, was observed 6 times more often in the group with combination of DM1 and AIT. Conclusion. Children with a combination of DM1 and AITare at high risk for decompensation of carbohydrate metabolism and the development of chronic DM1 complications regardless of the functional state of the thyroid gland. Selective screening for AIT (TSH, anti-TPO and thyroid ultrasound) in DM1 children is necessary already at the stage of diabetes manifestation. Further dynamic monitoring of children with APS 3, regardless of the initial functional state of the thyroid gland, should be carried out taking into account the established risks, more carefully, with annual monitoring of TSH level and screening for chronic complications.

Full Text

Restricted Access

About the authors

A. N Abdullaev

Ural State Medical University

D. V Litvinova

Ural State Medical University

N. I Rozhkov

Ural State Medical University

Aleksey V. Kiyaev

Ural State Medical University; Regional Children's Clinical Hospital, Yekaterinburg

Email: thyroend@mail.ru
Dr. Sci. (Med.), Professor at the Department of Hospital Pediatrics

References

  1. Valenzise M, Aversa T., Saccomanno A., et al. Epidemiological and clinical peculiarities of polyglandular syndrome type 3 in pediatric age. Ital J Pediatr. 2017;43(1):69. doi: 10.1186/s13052-017-0386-4.
  2. Kakleas K., Soldatou A., Karachaliou F, Karavanaki K. Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun Rev. 2015;14(9):781-97. doi: 10.1016/j.autrev.2015.05.002.
  3. Tomer Y, Dolan L.M., Kahaly G., et al. Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes. J Autoimmun. 2015;60:32-39. Doi:10.1016/j. jaut.2015.03.006.
  4. Bojanin D., Milenkovic T., Vekic J., et al. Effects of co-existing autoimmune diseases on serum lipids and lipoprotein subclasses profile in paediatric patients with type 1 diabetes mellitus. Clin Biochem. 2018;54:11 17. doi: 10.1016/j.clinbiochem.2018.01.026
  5. Benvenga S., Pintaudi B., Vita R., et al. Serum Thyroid Hormone Autoantibodies in Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2015;100(5):1870-78. doi: 10.1210/jc.2014-3950.
  6. Maratou E., Hadjidakis D., Kolias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009;160(5): 785-90. doi: 10.1530/eje-08-0797.
  7. Hansen M.P, Matheis N., Kahaly G.J. Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes. 2015;6(1):67-79. doi: 10.4239/wjd.v6.i1.67.
  8. Ларина А.А., Трошина Е.А Аутоиммунные заболевания, ассоциированные с сахарным диабетом 1-го типа: возможное взаимовлияние. Проблемы эндокринологии. 2013;59(1): 35-43. doi: 10.14341/probl201359135-43. [Larina A.A., Troshina E.A. Autoimmune diseases associated wth type 1 diabetes mellitus: possible interplay. Problemy Endocrinologii. 2013;59(1): 35-43. (In Russ.)]. Doi: 10.14341/ probl201359135-43.
  9. Moulton V Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol. 2018;9.
  10. Ruggeri R., Vicchio T., Crstani M., et al. Oxidative Stress and Advanced Glycation End Products in Hashimoto’s Thyroiditis. Thyroid. 2016;26(4):504 11. doi: 10.1089/thy.2015.0592
  11. Ramasamy R., Yan S., DAgati V, Schmidt A. Receptor for Advanced Glycation Endproducts (RAGE): A Formidable Force in the Pathogenesis of the Cardiovascular Complications of Diabetes & Aging. Curr Mol Med. 2007;7(8):699-710. doi: 10.2174/156652407783220732.
  12. Brunvand L., Heier M., Brunborg C., et al. Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function. BMC Cardiovasc Disord. 2017;17(1). Doi:10.1186/ s12872-017-0551-0.
  13. Rhee S., Kim Y. The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes Metab J. 2018;42(3):188. Doi:10.4093/ dmj.2017.0105.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies